RI
RegCell, Inc.
United States · Biotech
RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | $44M | Playground Global — LeadAlumni Ventures — ParticipantFast Track Initiative — ParticipantGlobal Brain — ParticipantKyoto iCAP — ParticipantLG Technology Ventures — ParticipantMedical Incubator Japan — ParticipantMitsui Chemicals — ParticipantOsaka University Venture Capital — ParticipantThe University of Tokyo Edge Capital Partners (UTEC) — Participant |